CONSORT diagram: Study cohort and flow of emulated trial.
<p>U07.1, COVID-19 ICD-10 code; PCR, polymerase chain reaction; PASC, post-acute sequelae of COVID-19.</p>
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | , , , , , , , , , , , , , , , |
| Published: |
2025
|
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1852016587479973888 |
|---|---|
| author | Alexander Preiss (11725774) |
| author2 | Abhishek Bhatia (15224489) Leyna V. Aragon (22250805) John M. Baratta (15224486) Monika Baskaran (22250808) Frank Blancero (22250811) Michael Daniel Brannock (22272395) Robert F. Chew (4397755) Iván Díaz (5662771) Megan Fitzgerald (14875194) Elizabeth P. Kelly (20577511) Andrea G. Zhou (22250814) Thomas W. Carton (16979380) Christopher G. Chute (8754639) Melissa Haendel (14045) Richard Moffitt (12043127) Emily Pfaff (8563671) |
| author2_role | author author author author author author author author author author author author author author author author |
| author_facet | Alexander Preiss (11725774) Abhishek Bhatia (15224489) Leyna V. Aragon (22250805) John M. Baratta (15224486) Monika Baskaran (22250808) Frank Blancero (22250811) Michael Daniel Brannock (22272395) Robert F. Chew (4397755) Iván Díaz (5662771) Megan Fitzgerald (14875194) Elizabeth P. Kelly (20577511) Andrea G. Zhou (22250814) Thomas W. Carton (16979380) Christopher G. Chute (8754639) Melissa Haendel (14045) Richard Moffitt (12043127) Emily Pfaff (8563671) |
| author_role | author |
| dc.creator.none.fl_str_mv | Alexander Preiss (11725774) Abhishek Bhatia (15224489) Leyna V. Aragon (22250805) John M. Baratta (15224486) Monika Baskaran (22250808) Frank Blancero (22250811) Michael Daniel Brannock (22272395) Robert F. Chew (4397755) Iván Díaz (5662771) Megan Fitzgerald (14875194) Elizabeth P. Kelly (20577511) Andrea G. Zhou (22250814) Thomas W. Carton (16979380) Christopher G. Chute (8754639) Melissa Haendel (14045) Richard Moffitt (12043127) Emily Pfaff (8563671) |
| dc.date.none.fl_str_mv | 2025-09-15T18:00:06Z |
| dc.identifier.none.fl_str_mv | 10.1371/journal.pmed.1004711.g001 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/figure/CONSORT_diagram_Study_cohort_and_flow_of_emulated_trial_/30131772 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Medicine Neuroscience Biotechnology Immunology Cancer Mental Health Infectious Diseases Virology Computational Biology xlink "> preventing xlink "> although stratified analyses suggest public health priority pooled individual record medical history covariates charlson comorbidity index causal interpretation relies study &# 8212 paxlovid held promise subsequent pasc incidence overall pasc incidence estimated paxlovid ’ small protective effect nationally sampled cohort absolute risk difference 19 vaccination status paxlovid treatment due patients prescribed paxlovid six sequential trials contemporary study period trial start day ard − 1 incident respiratory symptoms long covid onset study ’ pasc incidence paxlovid treatment sequential trials sequential trial see paxlovid paxlovid may respiratory symptoms pasc preventive long covid treatment group risk patients 738 patients − 0 wide range significant effect severe covid secondary outcomes remained untreated relative risk primary outcome main limitation level data incident cognitive definitive solution |
| dc.title.none.fl_str_mv | CONSORT diagram: Study cohort and flow of emulated trial. |
| dc.type.none.fl_str_mv | Image Figure info:eu-repo/semantics/publishedVersion image |
| description | <p>U07.1, COVID-19 ICD-10 code; PCR, polymerase chain reaction; PASC, post-acute sequelae of COVID-19.</p> |
| eu_rights_str_mv | openAccess |
| id | Manara_586d3370bfa3d64da04f459797b07fff |
| identifier_str_mv | 10.1371/journal.pmed.1004711.g001 |
| network_acronym_str | Manara |
| network_name_str | ManaraRepo |
| oai_identifier_str | oai:figshare.com:article/30131772 |
| publishDate | 2025 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | CONSORT diagram: Study cohort and flow of emulated trial.Alexander Preiss (11725774)Abhishek Bhatia (15224489)Leyna V. Aragon (22250805)John M. Baratta (15224486)Monika Baskaran (22250808)Frank Blancero (22250811)Michael Daniel Brannock (22272395)Robert F. Chew (4397755)Iván Díaz (5662771)Megan Fitzgerald (14875194)Elizabeth P. Kelly (20577511)Andrea G. Zhou (22250814)Thomas W. Carton (16979380)Christopher G. Chute (8754639)Melissa Haendel (14045)Richard Moffitt (12043127)Emily Pfaff (8563671)MedicineNeuroscienceBiotechnologyImmunologyCancerMental HealthInfectious DiseasesVirologyComputational Biologyxlink "> preventingxlink "> althoughstratified analyses suggestpublic health prioritypooled individual recordmedical history covariatescharlson comorbidity indexcausal interpretation reliesstudy &# 8212paxlovid held promisesubsequent pasc incidenceoverall pasc incidenceestimated paxlovid ’small protective effectnationally sampled cohortabsolute risk difference19 vaccination statuspaxlovid treatment duepatients prescribed paxlovidsix sequential trialscontemporary study periodtrial start dayard − 1incident respiratory symptomslong covid onsetstudy ’pasc incidencepaxlovid treatmentsequential trialssequential trialsee paxlovidpaxlovid mayrespiratory symptomspasc preventivelong covidtreatment grouprisk patients738 patients− 0wide rangesignificant effectsevere covidsecondary outcomesremained untreatedrelative riskprimary outcomemain limitationlevel dataincident cognitivedefinitive solution<p>U07.1, COVID-19 ICD-10 code; PCR, polymerase chain reaction; PASC, post-acute sequelae of COVID-19.</p>2025-09-15T18:00:06ZImageFigureinfo:eu-repo/semantics/publishedVersionimage10.1371/journal.pmed.1004711.g001https://figshare.com/articles/figure/CONSORT_diagram_Study_cohort_and_flow_of_emulated_trial_/30131772CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/301317722025-09-15T18:00:06Z |
| spellingShingle | CONSORT diagram: Study cohort and flow of emulated trial. Alexander Preiss (11725774) Medicine Neuroscience Biotechnology Immunology Cancer Mental Health Infectious Diseases Virology Computational Biology xlink "> preventing xlink "> although stratified analyses suggest public health priority pooled individual record medical history covariates charlson comorbidity index causal interpretation relies study &# 8212 paxlovid held promise subsequent pasc incidence overall pasc incidence estimated paxlovid ’ small protective effect nationally sampled cohort absolute risk difference 19 vaccination status paxlovid treatment due patients prescribed paxlovid six sequential trials contemporary study period trial start day ard − 1 incident respiratory symptoms long covid onset study ’ pasc incidence paxlovid treatment sequential trials sequential trial see paxlovid paxlovid may respiratory symptoms pasc preventive long covid treatment group risk patients 738 patients − 0 wide range significant effect severe covid secondary outcomes remained untreated relative risk primary outcome main limitation level data incident cognitive definitive solution |
| status_str | publishedVersion |
| title | CONSORT diagram: Study cohort and flow of emulated trial. |
| title_full | CONSORT diagram: Study cohort and flow of emulated trial. |
| title_fullStr | CONSORT diagram: Study cohort and flow of emulated trial. |
| title_full_unstemmed | CONSORT diagram: Study cohort and flow of emulated trial. |
| title_short | CONSORT diagram: Study cohort and flow of emulated trial. |
| title_sort | CONSORT diagram: Study cohort and flow of emulated trial. |
| topic | Medicine Neuroscience Biotechnology Immunology Cancer Mental Health Infectious Diseases Virology Computational Biology xlink "> preventing xlink "> although stratified analyses suggest public health priority pooled individual record medical history covariates charlson comorbidity index causal interpretation relies study &# 8212 paxlovid held promise subsequent pasc incidence overall pasc incidence estimated paxlovid ’ small protective effect nationally sampled cohort absolute risk difference 19 vaccination status paxlovid treatment due patients prescribed paxlovid six sequential trials contemporary study period trial start day ard − 1 incident respiratory symptoms long covid onset study ’ pasc incidence paxlovid treatment sequential trials sequential trial see paxlovid paxlovid may respiratory symptoms pasc preventive long covid treatment group risk patients 738 patients − 0 wide range significant effect severe covid secondary outcomes remained untreated relative risk primary outcome main limitation level data incident cognitive definitive solution |